Natixis Advisors LLC Has $53.07 Million Holdings in HCA Healthcare, Inc. $HCA

Natixis Advisors LLC trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 3.8% in the third quarter, Holdings Channel reports. The fund owned 124,507 shares of the company’s stock after selling 4,889 shares during the quarter. Natixis Advisors LLC’s holdings in HCA Healthcare were worth $53,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in HCA. Clearstead Trust LLC lifted its holdings in shares of HCA Healthcare by 311.8% during the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after buying an additional 53 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock valued at $32,000 after purchasing an additional 34 shares during the last quarter. Twin Peaks Wealth Advisors LLC acquired a new stake in HCA Healthcare in the 2nd quarter worth $40,000. Compound Global Advisors LLC acquired a new position in shares of HCA Healthcare during the third quarter valued at about $44,000. Finally, True Wealth Design LLC grew its position in HCA Healthcare by 179.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the company’s stock worth $47,000 after buying an additional 70 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $545.88 on Tuesday. HCA Healthcare, Inc. has a 52 week low of $310.18 and a 52 week high of $552.90. The company has a market capitalization of $122.07 billion, a PE ratio of 19.23, a P/E/G ratio of 1.64 and a beta of 1.34. The company’s fifty day moving average is $501.78 and its 200-day moving average is $466.79.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating analysts’ consensus estimates of $7.37 by $0.64. The firm had revenue of $19.51 billion for the quarter, compared to analyst estimates of $19.67 billion. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio is presently 10.15%.

Insiders Place Their Bets

In other news, EVP Michael R. Mcalevey sold 1,694 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $533.37, for a total value of $903,528.78. Following the completion of the sale, the executive vice president directly owned 8,853 shares in the company, valued at approximately $4,721,924.61. This trade represents a 16.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jennifer Berres sold 8,020 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $514.58, for a total transaction of $4,126,931.60. Following the sale, the senior vice president directly owned 11,993 shares in the company, valued at approximately $6,171,357.94. This represents a 40.07% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 15,214 shares of company stock valued at $7,797,595. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HCA has been the subject of a number of research reports. UBS Group raised their price objective on HCA Healthcare from $598.00 to $635.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of HCA Healthcare in a research report on Monday, December 29th. The Goldman Sachs Group boosted their price target on shares of HCA Healthcare from $520.00 to $558.00 and gave the company a “buy” rating in a report on Wednesday, January 28th. Jefferies Financial Group lifted their target price on shares of HCA Healthcare from $535.00 to $590.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. Finally, Oppenheimer raised their price target on shares of HCA Healthcare from $500.00 to $540.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Sixteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, HCA Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $534.50.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.